Danbury – October 27, 2026 -- CellsBin has received a Direct-to-Phase II Small Business Innovation Research (SBIR) award from the National Cancer Institute (NCI) to advance CB-Insight, its blood-based test for multiple myeloma, a cancer of plasma cells in the bone marrow.